Loading ...
Sorry, an error occurred while loading the content.

16286Fw: NATAP: HCV Protease Drug ITMN-191 Study Begins

Expand Messages
  • alleypat
    Dec 30, 2006
      NATAP http://natap.org/


      InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche

      December 20, 2006 - 1:21 PM

      BRISBANE, Calif., Dec. 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (NASDAQ:ITMN) announced today that the company and its partner Roche have received approval of the European Clinical Trial Authorization (CTA) for ITMN-191, the NS3/4A protease inhibitor, and have initiated a Phase 1a clinical trial evaluating ITMN-191 for the treatment of chronic hepatitis C virus (HCV) infection. The Phase 1a trial will assess safety, tolerability, pharmacokinetics and food affect in a double-blind, placebo-controlled single ascending dose study. The study is being conducted at one clinical trial site in Europe and will enroll approximately 74 healthy volunteers. InterMune expects to dose the first patient with ITMN-191 sometime in early January 2007.

      "Our preclinical research indicates ITMN-191 has the potential to be an important addition to therapy for HCV patients because of its favorable cross resistance and potency profiles, as well as pharmacokinetic results that support the exploration of twice-daily oral dosing in future clinical trials," said Lawrence M. Blatt, Ph.D., Chief Scientific Officer of InterMune. "The initiation of the Phase 1a human trial for ITMN-191 moves our HCV protease inhibitor program one step closer to the proof-of-concept Phase 1b clinical study in patients infected with HCV. We look forward to providing updates as we advance the program with our partner Roche."

      About HCV and HCV Protease Inhibitors
      According to the Centers for Disease Control and Prevention (CDC), an estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom 2.7 million are chronically infected. According to the World Health Organization (WHO), it is estimated that there are 170 million people worldwide afflicted with this disease. Currently available therapies are insufficient, creating a need for the development of novel therapeutic approaches. The HCV NS3/4A protease is an attractive drug target because of its potential involvement in viral replication and suppressive effects on host response to viral infection. Inhibitors of the HCV protease, such as ITMN-191, represent a promising new class of drugs for HCV.


      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.

      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv



      No virus found in this incoming message.
      Checked by AVG Free Edition.
      Version: 7.5.432 / Virus Database: 268.15.28/606 - Release Date: 12/28/2006 12:22 AM

      [Non-text portions of this message have been removed]